Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina represents a vital evolution in ophthalmic practice.
While the ongoing emergence of effective drugs and biologics for the treatment of retinal conditions has been a great boon to our patients, the burden of frequent intravitreal injections poses challenges to patient adherence and can result in suboptimal outcomes (Holz et al.).
Furthermore, sustained-release delivery of therapeutic agents to target tissues can provide consistent exposure of therapeutic agents with short half-lives that